LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study

Overview of attention for article published in Frontiers in oncology, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 19,529 followers.

Proud to announce that the results of ABCSG`s academic phase 2 trial LM02 have been published in the Journal Frontiers Oncology. For full article click here: https://t.co/ToD581RdX2

13 Sep 2023

Reply Repost Favourite

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study https://t.co/LARevhb4YS

25 Aug 2023

Reply Repost Favourite

RT @FrontOncology: New research: LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentiall…

17 Aug 2023

Reply Repost Favourite

New research: LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study: Background Twenty percent of colorectal cancer liver… #oncology https

17 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.